SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape
8.0
来源：
Nature
发布时间：
2025-09-02 23:33
摘要：
SOX2 is identified as a potent oncogenic driver in esophageal squamous carcinoma (ESCC), promoting global histone acetylation and reprogramming lipid metabolism. The study reveals that SOX2 enhances histone acetylation by recruiting lysine acetyltransferases and repressing fatty acid synthesis via ACSL5 suppression. Clinical analysis shows a positive correlation between SOX2 expression and histone acetylation in ESCC tumors, suggesting its potential as a therapeutic target. These findings highlight SOX2's role in tumorigenesis and may present early investment opportunities in targeted cancer therapies.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
SOX2 enhances global histone acetylation in ESCC cells.
SOX2 expression correlates negatively with ACSL5 and positively with histone acetylation in clinical esophageal squamous tumors.
SOX2 drives tumorigenesis in part by suppressing ACSL5 expression.
真实性检查
否
AI评分总结
SOX2 is identified as a potent oncogenic driver in esophageal squamous carcinoma (ESCC), promoting global histone acetylation and reprogramming lipid metabolism. The study reveals that SOX2 enhances histone acetylation by recruiting lysine acetyltransferases and repressing fatty acid synthesis via ACSL5 suppression. Clinical analysis shows a positive correlation between SOX2 expression and histone acetylation in ESCC tumors, suggesting its potential as a therapeutic target. These findings highlight SOX2's role in tumorigenesis and may present early investment opportunities in targeted cancer therapies.